| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 05-17-2024 | 03-31-2024 | 10-Q | |
| 2 | 03-21-2024 | 12-31-2023 | 10-K | |
| 3 | 11-09-2023 | 09-30-2023 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $9 price target.
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survi...
Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $9 price target.
Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.24)
Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell...
The Company is canceling its previously announced earnings release and call scheduled for before U.S. market open on May 14, 20...
